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Abstract (250 words) 
 
Background To explore the effect of ivabradine on angina-related quality of life 
(QoL) in patients participating in the SIGNIFY Quality of Life substudy. 
Methods and results QoL was evaluated in a prespecified subgroup of SIGNIFY 
patients with angina (Canadian Cardiovascular Society class ≥2 at baseline) using the 
Seattle Angina Questionnaire (SAQ) and a generic visual analogue scale (VAS) on 
health status. Data were available for 4187 patients (2084 ivabradine, 2103 placebo). 
There were improvements in QoL in both treatment groups. The primary outcome of 
change in physical limitation score at 12 months was 4.56 points for ivabradine versus 
3.40 points for placebo (E, 0.96, 95% CI, –0.13– 2.05, p=0.085).The ivabradine-
placebo difference in physical limitation score was significant at 6 months (p=0.048). 
At 12 months, the VAS and the other SAQ dimensions were higher among 
ivabradine-treated patients, notably angina frequency (p<0.001) and disease 
perception (p=0.006). Patients with the worst QoL at baseline (i.e. those in the lowest 
tertile of score) had the best improvement in QoL over 12 months, with improvements 
in the physical limitation and a significant reduction in angina frequency (p=0.034). 
The effect on QoL was maintained over the study duration, and ivabradine patients 
had better scores on angina frequency at every visit to 36 months. 
Conclusion Treatment with ivabradine did not affect the primary outcome of change 
in physical limitation score at 12 months. It did produce consistent improvements in 
in other self-reported QoL parameters related to angina pectoris, notably in terms of 
angina frequency and disease perception. 
Clinical trial registration ISRCTN61576291. 
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Introduction 
 
Chronic stable angina has a major negative impact on health-related quality of life 
(QoL) due to pain, limited exercise tolerance, and poor general health status.1-3 
Angina causes disability and impairment of QoL at a relatively younger age than 
other cardiovascular diseases such as heart failure. Moreover, despite widespread use 
of coronary revascularization, the rate of disability related to angina is increasing; in 
one report, the years lived with disability increased by 11% from 1990 to 2010.4 The 
symptomatic management of angina is expected to improve QoL by reducing the 
severity and/or frequency of angina symptoms. Indeed, angina relief is a major goal of 
treatment for stable coronary artery disease (CAD), and in this sense quantifying the 
burden of angina from the perspective of the patient should be regarded as very 
important. 
 
The SIGNIFY (Study Assessing the Morbidity–Mortality Benefits of the If Inhibitor 
Ivabradine in Patients with Coronary Artery Disease) trial included 19 102 patients 
with CAD without clinical heart failure, who received ivabradine up to a dosage of 10 
mg bid or placebo. The main results were neutral with no effect of treatment on the 
primary composite endpoint of cardiovascular death or nonfatal myocardial infarction 
over a median follow-up of 27.8 months (p=0.20).5 The use of ivabradine was 
associated with an increase in the incidence for primary composite endpoint in a 
prespecified subgroup of 12 049 patients with Canadian Cardiovascular Class (CCS) 
class II or higher angina at baseline (p=0.02). Analyses of the antianginal effect of 
ivabradine in the same angina subgroup were in line with the symptomatic use of the 
agent in patients with stable angina pectoris. There were improvements in CCS angina 
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class versus placebo (p=0.01) and a trend towards lower incidence of elective 
coronary revascularization (p=0.058).5 In this article, we present the results of the 
SIGNIFY Quality of Life substudy, in which the Seattle Angina Questionnaire (SAQ) 
and a visual analogue scale (VAS) were used to assess the effect of treatment with 
ivabradine on angina-related QoL.  
 
Methods 
 
Study design and patients 
SIGNIFY was a randomized, double-blind, placebo-controlled trial in patients with 
stable CAD without clinical heart failure. The design and results of SIGNIFY have 
been described elsewhere.5,6 The protocol of the study was approved by the ethics 
committee at each participating institution, and all patients gave written informed 
consent prior to entry to the study. Briefly, SIGNIFY included 19 102 patients with 
documented stable CAD, a heart rate of 70 bpm or higher in sinus rhythm, and at least 
one major or two minor adverse prognostic factors. A prespecified subgroup of 
12 049 patients had CCS angina class II or higher at baseline. The presence of angina 
in this subgroup would be expected to have a substantial impact on QoL, and 
constituted the basis for the QoL substudy population for exploration of the effect of 
ivabradine treatment on QoL.  
 
After a 2- to 4-week placebo run-in, all participants were randomly allocated to 
receive ivabradine at a dose of 7.5 mg bid or matching placebo (except for those 75 
years or older, who received 5.0 mg bid). Randomization was stratified by center and 
angina status. At every visit, dosage was adjusted (5, 7.5, or 10 mg bid) to a target 
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heart rate of 55 to 60 bpm. Treatment was stopped if the heart rate was less than 45 
bpm on the lowest dosage, or persisted at less than 50 bpm for 1 week, and in case of 
symptomatic bradycardia. In addition, all patients received stable background therapy 
according to guidelines in force at the time of inclusion.5  
 
Countries for which a validated version of the SAQ was available in the local 
language(s) could participate in the SIGNIFY QoL substudy. All centers in each 
selected country were invited to participate in the substudy, and all patients in those 
centers with symptoms of angina at baseline (CCS angina class II or higher) were 
invited to participate in the substudy. Substudy patients gave specific informed 
consent for the QoL substudy in addition to that for the main study. 
 
Quality of life questionnaire 
QoL was assessed using the SAQ, as well as a generic visual analogue scale (VAS) at 
baseline, 6, 12, 24, and 36 months and last visit, , to record the patient's evaluation of 
his or her own health status. At each substudy visit, the patients self-administered the 
SAQ and the VAS before the other investigations related to the main study, to avoid 
any influence of the subsequent discussion with the physician, who was not aware of 
the QoL data reported by the patient.  
 
The SAQ is a validated 19-item questionnaire that measures 5 dimensions (physical 
limitation, angina frequency, disease perception, angina stability, and treatment 
satisfaction) to evaluate QoL specifically in angina populations.7 SAQ scores were 
calculated by summing items within a dimension and transforming them to a 0 to 100 
graded scale. For all dimensions, a higher score indicates better health status or 
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satisfaction. Quality control measures were implemented for both the SAQ and VAS 
to confirm their reliability and validity independently of treatment group in the 
substudy population.   
 
The primary endpoint was change from baseline at 12 months in the physical 
limitation dimension of the SAQ; this was selected as the primary endpoint since it 
was considered essential to measure the most direct functional impact of angina. 
Secondary endpoints included 12-month change in the angina frequency as well as 
12-month changes in the other SAQ dimensions and the VAS. Analyses were also 
carried out in subgroups defined according to the baseline characteristics of heart rate 
(<75 or ≥75 bpm), age (<65 or ≥65 years), CCS class of angina (class II or class 
III/IV), gender, and use of beta-blockers at randomization (Yes/No). The change in 
quality of life over the duration of the study was also assessed by plotting QoL 
parameters at 6, 12, 24, and 36 months. A complementary analysis, including a 
comparison of the proportion of patients with changes deemed as clinically relevant, 
was performed to assess the effect of treatment on change in QoL in the population 
divided according to tertiles of baseline physical limitation score and angina 
frequency score. A change in physical limitation score of 8 points or more or a change 
in angina frequency score of 20 points or more were considered as clinically 
significant.8 Similarly, changes in disease perception, treatment satisfaction, and 
angina stability were considered as clinically significant if they were 16, 12, and 25 
points or more, respectively. 
 
Statistical methods 
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It was estimated that a sample size of 4500 patients would allow detection of a 
between-group difference on the SAQ physical limitation dimension (effect size of 
0.15, 95% power using a two-sided test, and 5% type I error). 
 
Baseline characteristics are presented as means (SD) for continuous variables and 
counts (percentages) for categorical variables in the substudy population. All analyses 
are presented in a population comprised of randomized patients included in the QoL 
substudy with baseline CCS class II or higher with a record of physical limitation on 
the SAQ at baseline and at least one postbaseline evaluation during the first 12 
months of follow-up, and who had taken at least one dose of study treatment. Missing 
QoL follow-up data were dealt with using the last observation carried forward 
method; patients who died were attributed a score of zero at next scheduled visit. The 
difference between ivabradine and placebo on change in QoL was estimated using a 
parametric covariance analysis with country as a random effect and baseline as a 
covariate. Results are presented as estimates (E) with associated standard errors (SEs), 
two-sided 95% confidence intervals (CI), and p values. A range of sensitivity analyses 
were carried out, including unadjusted analyses, an analysis that did not involve 
imputing a score of zero for those who died, and a mixed model with repeated 
measures. The proportions of patients with clinically relevant changes were compared 
using a logistic regression adjusted for baseline and country and presented as p values. 
All statistical analyses were performed using SAS software (version 9.2). 
 
Results 
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The substudy included 5231 patients (2618 ivabradine, 2613 placebo) in 591 centers 
in 35 countries. Of these, 4187 patients (2084 ivabradine, 2103 placebo) had CCS 
class II or higher angina, had received at least one dose of study treatment, and had at 
least one baseline and one postbaseline evaluation of physical limitation score on the 
SAQ during the first 12 months (Figure 1). The SAQ and VAS were fully completed 
at baseline in 4064 (97%) and 4111 patients (98%), respectively. The main reasons 
for not completing the QoL evaluation at any postbaseline visit for ongoing patients 
was center mistake (24%) or the patient not attending the visit or only being contacted 
by telephone (39%). Centre mistake was the reason given for not completing the 
evaluation in 67% of cases at 6 months; subsequently, reminders were sent to 
investigators and center mistake was a less common reason for the rest of the trial 
(17% at 3 years). The median follow-up of the substudy patients was 35.4 months in 
the ivabradine group and 35.3 months in the placebo group. The mean dosage of 
ivabradine in that treatment group was 8.24±1.77 mg bid. 
 
There were no differences between the two treatment groups at baseline (Table 1), 
and there were no relevant differences in the substudy population compared with the 
angina patients in the main study.5 The mean age of the population was 64.1±7.0 
years and 72% were male. Mean heart rate at baseline was 77.0±6.8 bpm. More than 
three-quarters of the population had previously had a myocardial infarction (78%) and 
half (54%) coronary revascularization. The patients were receiving guideline-
recommended background therapy for their angina, including beta-blockers (87%), 
dihydropyridine calcium channel blockers (24%), and organic nitrates (54%). At 
baseline, mean physical limitation score was 61.12±19.71 and angina frequency score 
was 67.32±21.43. Patients in the ivabradine group were more likely to move to a 
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lower CCS class (25% of ivabradine patients had an improvement at 3 months versus 
17% of placebo patients, p<0.0001; this effect was consistent at 6, 12, and 24 months, 
p<0.0001, p=0.0001, and p=0.006, respectively).  
 
QoL improved over 12 months in placebo patients as well as in ivabradine patients 
(Table 2). The primary outcome of change in physical limitation score at 12 months 
was 4.56 points in the ivabradine group versus 3.40 points in the placebo group (E, 
0.96, 95% CI, –0.13– 2.05, p=0.085) (Figure 2). There was evidence of an early 
impact of ivabradine on physical limitation dimension with a significant treatment-
placebo difference at 6 months (E, 1.04, 95% CI, 0.01 to 2.07, p=0.048). There were 
significant ivabradine–placebo differences on the other SAQ dimensions and the VAS 
at 12 months (Table 2, Figure 2). Notably, there were significant improvements in 
the angina frequency and disease perception dimensions with ivabradine versus 
placebo at 12 months (angina frequency: 11.01 versus 8.48 points, respectively, E, 
2.32, 95% CI, 1.17 to 3.48, p<0.001; disease perception: 10.57 versus 8.61 points, 
respectively, E, 1.57, 95% CI, 0.46 to 2.69, p=0.006). Similar results were found in 
sensitivity analyses including unadjusted analyses, an approach that did not involve 
imputing a score of zero for those who died, and a mixed model with repeated 
measures (data not shown). Subgroup analyses including angina class, resting heart 
rate, and beta-blocker intake at baseline, sex and age showed consistent results in the 
same direction for physical limitation and angina frequency scores (Figure 3).  
 
Patients with the worst QoL at baseline (i.e. those in the lowest tertile of score at 
baseline) generally had the best improvement in QoL over 12 months. The patients in 
the lowest tertile of physical limitation score at baseline (1344 patients, score <52.78 
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points) had a clinically significant increase by 13.44 points in the ivabradine group at 
12 months and 12.04 points in the placebo group (E, 1.12, 95% CI, –1.04 to 3.27, 
p=0.31). Similarly, the patients in the lowest tertile of angina frequency score at 
baseline (979 patients, score <60 points) had the greatest and clinically significant 
improvement at 12 months (increases of 27.72 and 24.47 points, respectively) with a 
significant between-group difference in favor of ivabradine (E, 3.06, 95% CI, 0.23 to 
5.89, p=0.034).  
 
In our substudy, 42.5% of ivabradine patients reached the clinically relevant8 change 
of 8 points or more in physical limitation score at 12 months versus 41.7% in the 
placebo group (OR, 1.02, 95% CI 0.90–1.17, p=0.72). Similarly, 41.0% of ivabradine 
patients reached a clinically relevant change of 20 points or more in angina frequency 
score versus 37.7% of the placebo group (OR, 1.20, 95% CI 1.04–1.38, p=0.012). A 
clinically significant change in disease perception (≥16 points) was observed in 45.3% 
of ivabradine patients versus 42.0% of placebo patients (OR, 1.16, 95% CI 1.01–1.33, 
p=0.037), while a clinically meaningful change in treatment satisfaction (≥12-points) 
was found in 34.2% of ivabradine patients versus 31.3% of placebo patients (OR, 
1.10, 95% CI 0.94–1.28, p=0.24). Finally, more ivabradine patients had a clinically 
meaningful change in angina stability (≥25-points) than placebo (36.4% versus 
32.8%, OR, 1.18, 95% CI 1.03–1.35, p=0.014). The patients in the lowest tertiles of 
QoL were more likely to reach a clinically relevant change. In this group, 58.6% of 
ivabradine patients and 56.0% of placebo patients reached a clinically relevant change 
in physical limitation (OR, 1.09, 95% CI 0.88–1.36, p=0.44), and 73.2% versus 
64.9%, respectively, reached a relevant change in angina frequency (OR, 1.47, 95% 
CI 1.12–1.94, p=0.006). 
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The change in QoL scores over the 3 years of the study is presented in Figure 4 for 
angina frequency and VAS scores. An increase in angina-related quality of life in the 
first 6 months of treatment was observed in both groups. The patients in the 
ivabradine group had higher values for angina frequency score at every visit, which 
was significantly better with ivabradine at 12, 24, and 36 months. For the VAS, the 
trend towards better scores with ivabradine was preserved over the whole study 
duration. 
 
Discussion 
 
There are few published studies of the impact of antianginal treatment on QoL in 
patients with angina pectoris in the long-term. With perhaps the sole exception to date 
of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive 
Drug Evaluation) trial,9 the few trials that have reported QoL in CAD populations are 
generally short-term, small-scale, and uncontrolled. At 6 months, there was a 
significant improvement in physical limitation with ivabradine, with a non-significant 
trend persisting after 12 months. In all other SAQ dimensions as well as in the health 
status assessed by VAS at the 12 month follow-up, patients in the ivabradine group 
fared significantly better than those on placebo. Thus, our results indicate that 
antianginal treatment with ivabradine has a positive effect on a range of QoL indices 
in patients with angina, despite of the lack of the long-term effect on physical 
limitation.. This is remarkable insofar as the SIGNIFY population had stable disease, 
for which they were receiving a good level of background antianginal therapy, and 
had no indication for revascularization at study entry, implying that their quality of 
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life was acceptable at the outset of the study. Our findings are also in line with 
previous smaller scale studies with ivabradine in angina, and also with larger-scale 
studies of the effect of ivabradine on disease-specific QoL in heart failure.10-12 
Treatment with ivabradine was associated with an improvement of angina frequency 
score and disease perception versus placebo (p<0.001 and p=0.006, respectively). 
Moreover, the improved QoL in the ivabradine group was consistent at 12 months for 
all SAQ dimensions,  the evaluation of health status VAS, and also for all of the 
predefined subgroups. The effect of ivabradine on angina frequency and VAS did not 
attenuate with time over the 3 years of the study. 
 
The SAQ changes observed in the global QoL SIGNIFY substudy population were 
lower than the levels that have been designated elsewhere as clinically relevant.8 On 
the other hand, in our study, more ivabradine patients reached clinically relevant 
changes in angina frequency, disease perception and treatment satisfaction scores than 
in the placebo group, with highly significant results for angina frequency in patients in 
the lowest tertile of QoL. QoL is a multidimensional assessment, and subjective 
experience of QoL can vary between individuals and be difficult to measure on the 
scale of a large population such as ours. It may therefore be difficult to show large 
differences over the long term (12 months), especially against a background of a 
strong natural tendency to improve in the placebo group.13 QoL data are important 
since they give a measure of the disease experience perceived by the patient, in terms 
of well-being, functional status, productivity, and the side effects of treatments; an 
impact on QoL may sometimes be regarded as more important than effects on clinical 
outcomes.14 Indeed, the aim of any antianginal treatment is to improve symptoms, and 
it cannot be assumed that this reflects an improvement in outcomes.5,15,16 In this 
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context, we should also note that the QoL values in SIGNIFY at baseline were similar 
or better than values reported in other trials in stable CAD and angina (COURAGE 
and the Efficacy of Ranolazine in Chronic Angina [ERICA] trial),9,17 in patients who 
were either awaiting coronary angioplasty or suffering from severe angina (more than 
3 attacks per week). This may also make it more difficult to show a large 
improvement. 
 
The main strength of our study is that with 4187 patients it is, to our knowledge, the 
largest assessment of QoL in patients with stable angina pectoris treated according to 
the guidelines, performed in a well-treated population using a validated disease-
specific questionnaire over a long follow-up time. The robustness of our results is 
demonstrated by the low rate of missing data and the good internal consistency and 
validity of the scales used. The main limitation is the generalizability of the study 
findings since the study enrolled patients in sinus rhythm with heart rate of 70 bpm or 
higher.  
 
In conclusion, this QoL substudy of the SIGNIFY trial was carried out in a large 
population of patients with stable CAD and symptomatic angina pectoris but without 
clinical heart failure, who were receiving guideline-recommended background 
treatment appropriate to their cardiovascular condition. Treatment with ivabradine 
appears to be associated with improvements in self-reported QoL related to angina 
pectoris, notably in terms of angina frequency and disease perception. 
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Figure legends 
 
Figure 1. Trial profile. 
Other reasons were generally nonmedical, including consent withdrawal or treatment refusal. Patients 
could have more than one reason for exclusion. 
 
Figure 2. Effect of treatment with ivabradine from baseline to 12 months on quality 
life on the Seattle Angina Questionnaire (SAQ) and a visual analogue scale.  
Values are estimates (E) of the adjusted difference between group means (ivabradine – placebo) and 
95% confidence interval (CI).  
 
Figure 3. Effect of treatment with ivabradine on quality life on the Seattle Angina 
Questionnaire (SAQ) from baseline to 12 months in subgroups divided according to 
baseline characteristics for the physical limitation score and the angina frequency 
score.  
Values are estimates (E) of the adjusted difference between group means (ivabradine – placebo) and 
95% confidence interval (CI). Patient numbers are given for physical limitation score. 
 
Figure 4. Angina frequency score (A) on the Seattle Angina Questionnaire (SAQ) 
and health status on the visual analogue scale (VAS) (B) over the 3 years in the 
substudy population. 
p values for ivabradine-placebo difference from a covariance analysis using the last observation carried 
forward method for the management of missing data. 
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Table 1. Baseline characteristics in the SIGNIFY Quality of Life Substudy 
population. 
Values are means±SD or n (%). There were no significant differences between the treatment groups in 
any of the baseline characteristics at p<0.05. ACE=angiotensin converting enzyme. CCB=calcium 
channel blocker. CCS=Canadian Cardiovascular Society.  
 
 Analyzed population (N=4187) 
Ivabradine (n=2084) Placebo 
(n=2103) 
Demographic characteristics    
Age (years) 64.1±6.8 64.1±7.1 
Body mass index (kg/m2) 29.1±4.4 29.0±4.6 
Heart rate (bpm) 76.9±6.7 77.2±6.9 
Male 1492 (72%) 1512 (72%) 
Ethnic origin   
• Caucasian 1915 (92%) 1933 (92%) 
• Asian 114 (5%) 101 (5%) 
• Other 54 (3%) 67 (3%) 
Systolic blood pressure (mm Hg) 130.0±12.7 129.9±12.7 
Diastolic blood pressure (mm Hg) 78.5±7.9 78.5±7.6 
Cardiovascular risk factors and medical history 
Coronary artery disease duration (years) 6.8±6.3 6.8±6.3 
Previous myocardial infarction 1624 (78%) 1656 (79%) 
Previous coronary revascularization 1127 (54%) 1140 (54%) 
CCS class II angina or higher 2084 (100%) 2103 (100%) 
Dyslipidemia (%) 1419 (68%) 1448 (69%) 
Diabetes mellitus (%) 718 (34%) 742 (35%) 
Peripheral artery disease (%) 352 (17%) 382 (18%) 
Current smoker (%) 429 (21%) 484 (23%) 
Hypertension (%) 1845 (88%) 1869 (89%) 
Left ventricular ejection fraction (%) 55.3±8.0 55.1±8.2 
Previous stroke (%) 136 (7%) 128 (6%) 
Concomitant treatments   
Antiplatelet or anticoagulants 2041 (98%) 2048 (97%) 
Aspirin 1899 (91%) 1907 (91%) 
Statins 1928 (93%) 1927 (92%) 
Beta-blockers 1802 (86%) 1842 (88%) 
ACE inhibitors  1358 (65%) 1364 (65%) 
Angiotensin II receptor blockers 413 (20%) 401 (19%) 
Dihydropyridine CCB 505 (24%) 509 (24%) 
Organic nitrates 1161 (56%) 1116 (53%) 
Diltiazem or verapamil 93 (4%) 97 (5%) 
Antidiabetic agents 629 (30%) 651 (31%) 
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Table 2. Quality of life results at 12 months on Seattle Angina Questionnaire (5 
dimensions) and health status on the visual analogue scale (VAS) in patients with 
baseline CCS class II or higher angina in patients with data. 
Values are means±SD or estimates (E) of the hazard ratio (ivabradine /placebo) with 95% confidence 
intervals (CI). LOCF= last observation carried forward. Adjusted for country and baseline value. 
Numbers of patients: a2056 ivabradine; 2081 placebo. b2075 ivabradine; 2090 placebo. c2040 
ivabradine; 2067 placebo.d2075 ivabradine; 2100 placebo. e2042 ivabradine; 2056 placebo.  
 
 Ivabradine (N=2084) Placebo (N=2103) 
Physical limitation   
• Baseline  60.86±19.90 61.38±19.52 
• 12 months (LOCF) 65.42±21.55 64.78±21.52 
• Difference 12 months - baseline 4.56±19.92 3.40±19.99 
• E (95% CI), p value 0.96 (–0.14–2.05), p=0.085 
 
Angina frequencya 
  
• Baseline  67.09±21.66 67.50±21.18 
• 12 months (LOCF) 78.09±20.99 75.98±22.06 
• Difference 12 months - baseline 11.00±22.12 8.47±22.81 
• E (95% CI), p value 2.32 (1.17–3.48), p<0.001 
 
Disease perceptionb 
  
• Baseline  55.25±20.52 55.87±20.64 
• 12 months (LOCF) 65.83±20.34 64.48±20.20 
• Difference 12 months - baseline 10.57±22.37 8.61±22.21 
• E (95% CI), p value 1.57 (0.46–2.69), p=0.006 
 
Angina stabilityc 
  
• Baseline  57.77±18.69 58.71±19.30 
• 12 months (LOCF) 64.11±23.28 62.63±23.25 
• Difference 12 months - baseline 6.34±28.18 3.92±28.69 
• E (95% CI), p value 1.61 (0.20–3.02), p=0.025 
 
Treatment satisfactiond 
  
• Baseline  80.81±15.85 81.85±15.34 
• 12 months (LOCF) 85.30±15.92 84.59±16.64 
• Difference 12 months - baseline 4.49±17.80 2.74±18.05 
• E (95% CI), p value 1.13 (0.22–2.04), p=0.015 
 
VASe 
  
• Baseline  62.52±15.97 62.74±15.91 
• 12 months (LOCF) 68.26±16.56 67.44±16.70 
• Difference 12 months - baseline 5.75±17.41 4.70±18.17 
• E (95% CI), p value 0.95 (0.03–1.86), p=0.044 
 
